Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers.
This protocol describes the common methodology to be applied to established health data registries across seven participating EU/EEA Member States to estimate vaccine effectiveness for Coronavirus disease 2019 (COVID-19) in children and adolescents aged 5-17 years old.
Measles cases are expected to continue increasing in the EU/EEA in the coming months due to sub-optimal vaccination coverage for measles-containing vaccines (MCV) in a number of EU/EEA countries.
In 2023, significant increases in the number of measles cases and outbreaks were observed globally, including in 40 of the 53 countries of the European region, and in at least ten EU/EEA countries.
The increase in cases of measles, a highly contagious, but vaccine-preventable disease, is a stark reminder that all Member States should maximise efforts to achieve and maintain high vaccination coverage for all vaccine-preventable diseases.
This protocol presents a common updated methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating European Union and European Economic Area (EU/EEA) countries.
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].
This generic protocol for ECDC studies describes the design and methods for a prospective multi-country cohort study of hospital-based healthcare workers (HCWs) to evaluate the effectiveness of COVID-19 vaccine in preventing laboratory-confirmed SARS-CoV-2 infection.